Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

The primary outcome of this study was a change in maximum walking distance after 52 weeks, while a key secondary outcome was improvement in symptoms and quality of life. According to study results, ...

Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Semaglutide, a GLP-1 receptor agonist ... Baseline functional capacity was moderately but not severely impaired. The median maximum walking distance on the inclined treadmill was 185·5 m (IQR ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Results from the ESSENCE Phase III clinical trial published in the New England Journal of Medicine show treating patients with semaglutide can halt and even reverse liver disease. The placebo ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...